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Aim To assess the immunomodulatory effect of tonsil-
derived mesenchymal stem cells (MSCs) on T-lymphocyte 
proliferation and cytokine production.
Methods Tonsils were obtained from children aged 3 to 
12 years (n = 15) who underwent tonsillectomy for ob-
structive sleep apnea from April 2012-October 2014 at the 
Merkur University Hospital, Zagreb. Tonsil-derived MSCs 
were co-cultured with peripheral blood mononuclear cells 
(PBMCs) and phytohemagglutinin as a mitogen. PBMCs 
were induced to differentiate into T helper 1 or T helper 2 
cells in the presence or absence of tonsil-derived MSCs, af-
ter which the production of interferon-gamma in T helper 
1 and interleukin-4 in T helper 2 cells was assessed.
Results Tonsil-derived MSC suppressed phytohemagglu-
tinin-induced proliferation of PBMCs. Compared with con-
trols, tonsil-derived MSC co-culture significantly decreased 
interferon-gamma production (P < 0.001) and increased in-
terleukin-4 production (P < 0.001).
Conclusion Tonsil-derived MSCs exert immunomodulato-
ry effects on T lymphocyte proliferation and T helper 1- and 
T helper 2-specific cytokine production.
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Multipotent mesenchymal stem cells (MSCs) differentiate 
into various tissues of mesodermal origin, including bone, 
cartilage, and adipose and muscle tissues (1). Although 
MSCs do not induce immune response in an immuno-
competent alloreactive host, in immunocompromised in-
dividuals they suppress T-, B-, natural killer, and dendritic 
cell proliferation and function (2-4). Several studies dem-
onstrated the immunosuppressive properties of MSCs, 
highlighting the inhibition of T cell proliferation as their 
most important effect (2,5). MSCs also suppress other T cell 
functions, such as activation, cytokine secretion, and cyto-
toxicity. They inhibit the expression of T cell surface activa-
tion markers, antigen-specific T cell maturation, formation 
of cytotoxic T-lymphocytes, and production of proinflam-
matory interferon-gamma (IFN-γ) in T helper 1 (Th1) cells 
and immunosuppressive interleukin-4 (IL-4) in T helper 2 
(Th2) cells (6,7).
MSCs for research and therapeutic use are mostly isolated 
from bone marrow; however, they can also be successfully 
isolated from many other adult tissues, including palatine 
tonsils (8-10). Palatine tonsils are an important alternative 
source of mesenchymal progenitor cells because of simple 
surgical access, lack of ethical dilemmas on tonsillectomy, 
and the fact that tonsils are generally removed in children 
and young adults, which provides young cells with high 
proliferation potential. In addition, since tonsillectomy is a 
common surgical procedure in children and adults, pala-
tine tonsils are one of the most abundant surgical residual 
tissues (11). Previous studies have demonstrated human 
palatine tonsils to be a good source of MSCs (8). Further-
more, protocols for MSC isolation and their cell culture 
conditions have been established, the cell surface markers 
have been characterized, and MSC differentiation into me-
sodermal tissues has been demonstrated (8).
Considering that tonsil-derived MSCs have comparable 
phenotypic properties and differentiation characteris-
tics to MSCs isolated from other tissues, we hypothesized 
that they may also exhibit immunomodulatory properties. 
Therefore, we assessed the immunomodulatory effect of 
tonsil-derived MSCs on T-lymphocyte proliferation and 
specific T-lymphocyte cytokine production in vitro.
MAteriAl AnD MethoDS
t-MSC isolation
Tonsils were obtained from children aged 3 to 12 years 
(n = 15) who underwent tonsillectomy for obstructive 
sleep apnea in the period April 2012-October 2014 at the 
Merkur University Hospital but had no other metabolic, 
cardiac, or respiratory diseases. The study was approved 
by the institutional review board of the Merkur Universi-
ty Hospital (KBM 03/11/1259, date of approval: March 17, 
2011), and parents signed the informed consent for study 
participation and data publication.
Tonsils were de-epithelialized and digested in the Roswell 
Park Memorial Institute (RPMI)-1640 medium (Invitrogen, 
Carlsbad, CA, USA) containing 210 U/mL collagenase type I 
(Invitrogen) and 90 kU/mL DNase I (Sigma-Aldrich, St. Lou-
is, MO, USA) for 30 minutes at 37°C. The cells were washed 
twice in 20% normal human serum (NHS)-RPMI and once 
with 10% NHS-RPMI after filtration through a wire mesh. 
The supernatant was discarded after centrifugation (cen-
trifuged for 10 minutes at 4000 RPM), and the cell pel-
let was resuspended in 50 mL phosphate buffered saline 
(PBS); after dilution, 10 mL suspension was distributed in 
five polypropylene tubes. Mononuclear cells were isolat-
ed by Ficoll-Paque (Amersham, GE Healthcare, Little Chal-
font, Buckinghamshire, UK) density gradient centrifuga-
tion of processed cell pellet, which was plated for 24 to 48 
hours in T-150 tissue culture flasks (Corning Incorporated, 
Corning, NY, USA). Non-adherent cells were subsequently 
removed by flushing with serum-free MSC expansion me-
dium (R&D Systems, Minneapolis, MN, USA).
t-MSC expansion
Serial passages of the cell culture were performed when 
tonsil-derived MSCs attained 80% confluence (as deter-
mined by phase contrast microscopy). Cells were washed 
twice with PBS, detached using 0.25% trypsin-EDTA solu-
tion (Gibco-BRL, Carlsbad, CA, USA), washed twice with ex-
pansion medium using centrifugation (1200 RPM for 5 min-
utes), and replated at 1:3 dilution under the same culture 
conditions. Cells obtained at passages 2 to 5 were used.
Cell surface epitope profiling – flow cytometry analysis
Tonsil-derived MSCs (>1 × 105 cells) were harvested and 
mixed with PBS containing 1% fetal bovine serum (FBS) 
(P+F mixture) with dilutions (1:100) of subsequent con-
jugated mouse IgG1κ anti-human monoclonal antibod-
ies: CD14-phycoerythrin (PE), CD31-PE, CD45- fluorescein 
isothiocyanate (FITC), CD73-PE, CD90-FITC, CD105-PE (BD 
Biosciences, San Jose, CA, USA), HLA-A, B, C-PE (MHC I), 
HLA-DR, DP, DQ-FITC (MHC II) (R&D Systems) over 1 
hour (at 4°C). Cell suspensions were washed twice 
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with P+F and resuspended in P+F for analysis on a flow 
cytometer (FACSCalibur, BD Biosciences) using the Cell-
Quest ProTM software (BD Biosciences). Positive staining 
was defined as fluorescence emission higher than the lev-
els obtained in more than 99% of the cells in a population 
stained with isotype controls.
In vitro differentiation
Tonsil-derived MSCs were induced for adipogenic, osteo-
genic, and chondrogenic differentiation. For adipogenic 
differentiation, cells were incubated for 3 weeks in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented 
with 10% FBS, 1 μM dexamethasone, 1 μg/mL insulin, and 
0.5 mM 3-isobutyl-1-methylxanthine (all Sigma-Aldrich). 
For osteogenic differentiation, cells were incubated for 
3 weeks in DMEM supplemented with 10% FBS, 10 nM 
dexamethasone, 50 μg/mL ascorbic acid-2-phosphate, 
10 mM β-glycerophosphate, and 10 nM 1,25 dihydroxyvi-
tamin D3 (Biomol International L.P., Plymouth Meeting, 
PA, USA). For chondrogenic differentiation, pelleted cul-
tures were incubated for 3 weeks in high-glucose DMEM 
supplemented with 100 nM dexamethasone, 40 μg/mL L-
proline, 100 μg/mL sodium pyruvate, 50 μg/mL ascorbic 
acid-2-phosphate, 10 ng/mL recombinant human trans-
forming growth factor-β3 (R & D Systems), and 50 mg/
mL insulin-transferrin-selenium-premix stock (BD Biosci-
ences).
total rnA isolation and quantitative reverse 
transcription polymerase chain reaction (qrt-PCr)
Total RNA samples were obtained from tonsil-derived 
MSCs after 3 weeks of culture using Trizol reagent (Invit-
rogen Corporation) and reverse-transcribed using random 
hexamers. Ten nanograms of complementary DNA (cDNA) 
and SYBR Green mix (Bio-Rad Laboratories, Irvine, CA, USA) 
was used for qRT-PCR with gene-specific primers (forward/
reverse) designed using GenBank cDNA sequences (Ta-
ble 1). Specific transcript levels were normalized to that 
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
and presented as fold increase over GAPDH levels using 
the 2(ΔCt) method, where ΔCt = Ct of target gene - Ct of 
GAPDH.
Primary mixed lymphocyte reaction
Peripheral blood was obtained from healthy human do-
nors (n = 15). Peripheral blood mononuclear cells (PBMCs) 
were segregated by using Ficoll-Hypaque density gradient 
centrifugation and subsequently mixed with RPMI-1640 
medium containing 10% FBS, 100 μg/mL streptomycin, 
100 U/mL penicillin, 2 mM glutamine, 0.1 mM non-essen-
tial amino acids, 1 mM sodium pyruvate, 20 mM HEPES, 
and 50 μM 2-mercaptoethanol. 1 × 105 PBMCs/100 μL (in 
triplicates) were seeded in 96-well round-bottom plates 
(BD Biosciences). T cell activator phytohemagglutinin was 
tABle 1. Primers for reverse transcription-polymerase chain reaction of differentiation-specific genes
Gene* Primer sequences (5’–3’) Position (bp) Predicted size (bp)
housekeeping gene
GAPDH Sense: GGGCTGCTTTTAACTCTGGT
Antisense: GCAGGTTTTTCTAGACGG
 134–835 702
Adipose tissue-specific genes
LPL Sense: GAGATTTCTCTGTATGGCACC
Antisense: CTGCAAATGAGACACTTTCTC
1261–1536 276
PPARγ Sense: GCTGTTATGGGTGAAACTCTG
Antisense: ATAAGGTGGAGATGCAGGCTC
 153–503 351
Bone-specific genes
ALP Sense: TGGAGCTTCAGAAGCTCAACACCA
Antisense: ATCTCGTTGTCTGAGTACCAGTCC
 122–575 454
OC Sense: ATGAGAGCCCTCACACTCCTC
Antisense: GCCGTAGAAGCGCCGATAGGC
  19–312 294
Cartilage-specific genes
AGN Sense: TGAGGAGGGCTGGAACAAGTACC
Antisense: GGAGGTGGTAATTGCAGGGAACA
6591–6910 350
COL2A1 Sense: CAGGTCAAGATGGTC
Antisense: TTCAGCACCTGTCTCACCA
1341–1717 377
*GAPDH – glyceraldehyde-3-phosphate dehydrogenase; LPL – lipoprotein lipase; PPARγ – peroxisome proliferator-activated receptor-γ; ALP – alkaline 
phosphatase; OC – osteocalcin; AGN – aggrecan; COL2A1 – collagen type II α1.
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used as a positive control mitogen (5 μg/mL). 5 × 104 of 
tonsil-derived MSCs were added to obtain a final volume 
of suspension of 300 μL per well. Plates were incubated 
for 72 hours, after which 1 μCi/[3H]-thymidine (GE Health-
care) was added to each well. After overnight incubation, 
incorporation of radioactivity was measured by liquid scin-
tillation counting. All tests were done in triplicates and re-
peated at least twice.
MSCs-induced t lymphocyte co-culture
Tonsil-derived MSCs and PBMCs were co-cultured in 12-
well plates (tonsil-derived MSCs to PBMCs ratio, 1:10) un-
der Th1- or Th2-inducing conditions. Control plates con-
tained tonsil-derived MSCs or PBMCs only. Th1-inducing 
medium contained anti-CD3 [5 μg/mL], anti-CD28 [1μg/
mL], recombinant human IL-2 [rhIL-2, 4 ng/mL], rhIL-12 
[1 μg/mL], and anti-IL-4 [1μg/mL]. Th2-inducing medium 
contained anti-CD3 [5 μg/mL], anti-CD28 [1 μg/mL], rhIL-2 
[4 ng/mL], rhIL-4 [1 μg/mL], and anti-IFN-γ [1 μg/mL] (Sig-
ma-Aldrich). After two days of incubation, the non-adher-
ent cells were collected from co-cultures and mixed with 
phytohemagglutinin (5 μg/mL) for further 24 hours. The 
levels of IFN-γ in Th1 and IL-4 in Th2 co-cultures were an-
alyzed using commercial enzyme-linked immunosobent 
assay kits (R&D Systems) as per manufacturer’s instructions 
and compared with controls.
Statistical analysis
All data are presented as mean ± standard deviation un-
less otherwise indicated. The sample size was based on 
literature search and is similar to that in other studies 
(3,7). The study power was calculated from sample size, 
effect size (Cohen’s d), and significance level. The lowest 
power was obtained for the assessment of IFN-γ secre-
tion. For IFN-γ levels, the Cohen’s d was 2.9 (signifying the 
large effect), so the significance level was set at 0.01 to 
correct for multiple comparisons (since there were three 
groups). The calculated power based on these data was 
at least 85%, while the power for other comparisons was 
even higher.
Normality of data distribution was tested by the Kolmog-
orov-Smirnov test. The differences between the groups in 
data from flow cytometry analysis of surface epitope pro-
files and real-time PCR analysis of differentiation-specific 
genes were assessed with the t test. The differences in cy-
tokine secretion were assessed with one-way ANOVA with 
Bonferroni post hoc correction. The significance level was 
set at P < 0.05. Statistical analysis was performed with the 
SPSS software, v. 23 (IBM Corp., Armonk, NY, USA).
reSultS
Cell isolation and proliferation
The total cell yield from each tonsil (n = 15) was in the 
range of 1-5 × 109. The majority of these cells were non-
adherent; most likely of hematopoietic origin. Approxi-
mately 0.1%-1% of the isolated cells remained adherent to 
flasks after repetitive irrigations with PBS and expansion-
medium changes. Tonsil-derived MSCs were homoge-
nous fibroblast-like with extended cytoplasmic processes 
(Figure 1).
Flow cytometry analysis of surface epitope profiles
Flow cytometric analysis showed non-hematopoietic and 
non-endothelial origin of tonsil-derived MSCs as they did 
not express CD45 and CD31. However, they were posi-
tive for characteristic MSC surface epitope markers, such 
as CD105, CD73, and CD90 (Figure 2). They also expressed 
MHC class I but not MHC class II molecules.
Multilineage differentiation potential
Tonsil-derived MSCs in passages 2-5 were treated with 
adipogenic, osteogenic, and chondrogenic supple-
ments. After 3 weeks of culture, qRT-PCR analysis of the 
differentiated cells revealed a significant increase 
FiGure 1. Microscopic view of unstained fibroblast-like tonsil-
derived mesenchymal stem cells with flat polygonal morphol-
ogy at passage 1. Magnification: 40 × .
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in lipoprotein lipase and peroxisome proliferator-activated 
receptor-γ expression in adipogenic cultures; osteocalcin 
and alkaline phosphatase expression in osteogenic cul-
tures; and aggrecan and collagen type II α1 expression in 
chondrogenic cultures (Figure 3).
inhibition of t cell proliferation
To assess the immunomodulatory effect of tonsil-derived 
MSCs on T cell responses, we first used in vitro assays of pro-
liferative T cell activity with phytohemagglutinin as a mito-
gen. Tonsil-derived MSC addition to cultured and phyto-
hemagglutinin-stimulated PBMCs robustly inhibited PBMC 
proliferation (Figure 4A). We observed a dose-dependent 
effect, except at 1:5 tonsil-derived MSC-to-PBMC ratio, 
when the effect of tonsil-derived MSCs was largely absent 
(Figure 4B). Paired t test showed that the immunosuppres-
sive effect of tonsil-derived MSCs on phytohemagglutinin-
stimulated proliferation of T cells was significant (P < 0.001). 
There was no significant self-induced effect (P = 0.150)
MSC-t cell interaction
We specifically focused on the production of Th1- and Th2-
specific cytokines in T cells generated under polarizing in 
vitro conditions. PBMCs undergoing Th1 differentiation 
without addition of tonsil-derived MSCs produced mod-
erate levels of IFN-γ. After the addition of tonsil-derived 
MSCs, these levels significantly decreased (P < 0.001) (Fig-
FiGure 2. Flow cytometry analysis of tonsil-derived mesen-
chymal stem cells (t-MSC). Cluster of differentiation (CD)14, 
CD34, CD45, CD73, CD90, CD105, major histocompatibility 
complex (MhC) i, and MhC ii were analyzed by fluorescent 
conjugated antibodies. the expression of each epitope is 
presented as the percentage of positive expression relative to 
the isotype control.
FiGure 3. Gene expression analysis of differentiated tonsil-
derived mesenchymal stem cells. Lipoprotein lipase (LPL) and 
proliferation-activated receptor-gamma (PPARγ) are genes 
involved in adipogenesis, osteocalcin (OC) and alkaline 
phosphatase (ALP) are genes involved in osteogenesis, and ag-
grecan (AGN) and collagen type II α1 (COL2) are genes involved 
in chondrogenesis. Gene expression analysis was performed 
at the beginning of culture (day 0) and at day 21. expression 
levels were normalized to that of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDh), and the results are reported as 
marker gene vs GAPDh ratios using the formula 2∆Ct ( × 100). 
Values are mean ± standard deviation (n = 2). error bars repre-
sent standard deviation.
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ure 5A). In Th2 cells, addition of tonsil-derived MSCs sig-
nificantly increased IL-4 production (P < 0.001) when com-
pared with baseline IL-4 levels.
DiSCuSSion
Our study identified a potent immunomodulatory effect of 
human tonsil-derived MSCs on proliferative and cytokine 
production. In the presence of tonsil-derived MSCs, T cells 
exhibited significantly decreased proliferation, decreased 
FiGure 4. tonsil-derived mesenchymal stem cells (t-MSCs) in-
hibited phytohemagglutinin (PhA)-stimulated t cell prolifera-
tion in a dose-dependent manner. Peripheral blood mononu-
clear cells (105 cells) with 5 μg/ml PhA were incubated for 72 
hours in the absence or presence of t-MSCs (5 × 104 or varying 
ratios). (A) Cell proliferation based on [3h]-thymidine uptake. 
t-MSCs inhibited the t cell proliferation. the value of 100% 
was set at the proliferative response (counts per minute per 
culture) of PhA-stimulated t cell proliferation. All values are 
mean ± standard deviation of triplicates. (B) t-MSCs demon-
strated a dose-dependent suppression of PhA-stimulated t 
cell proliferation. results (n = 3) are expressed as percentage 
relative to t cell proliferation without addition of t-MSCs (the 
value of 100%). error bars represent standard deviation. Gray 
bars – without t-MSCs; white bars – with t-MSCs.
FiGure 5. tonsil-derived mesenchymal stem cells (t-MSCs) 
were co-cultured with peripheral blood mononuclear cells 
under t helper 1 (th1) or t helper 2 (th2)-inducing conditions. 
(A) in the presence of t-MSCs, th1 cells showed >50% decrease 
in interferon-gamma (iFn-γ) production and (B) th2 showed 
>300% increase in interleukin-4 (il-4) production compared 
with controls without t-MSCs. Values indicate the change in 
cytokine secretion (mean ± standard deviation) in the absence 
or presence of t-MSCs in three independent experiments. error 
bars represent standard deviation.
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IFN-γ production, and increased IL-4 production, which dif-
fers from the typical inflammatory profile.
Our findings extend the results of earlier studies that 
showed that other MSCs (bone marrow, Wharton’s jelly, 
and fat tissue) exerted immunomodulatory effects on CD4+ 
and CD8+ T cells (12) and that tonsil-derived MSCs in mouse 
models modulated human immune responses (13).
Compared with controls, we observed >50% decrease 
in IFN-γ secretion in Th1 cells and >300% increase in IL-4 
production in Th2 cells when they were co-cultured with 
tonsil-derived MSCs. This is similar to other studies that 
showed that MSCs can alter immune cell response by in-
hibiting proinflammatory TNF-α and IFN-γ and increasing 
anti-inflammatory IL-4 and IL-10 secretion (6).
Both autologous and allogeneic MSCs suppress CD4+ Th 
cells and CD8+ cytotoxic T-lymphocytes (14,15). This sup-
pression of T cells may be direct, or indirect through mod-
ulatory action on antigen-presenting cells (16). Another 
mechanism is the arrest in the G0/G1 phase of the T cell 
cycle and reduction in IFN-γ, IL-2, and TNF-α production 
(6). MSCs can also suppress many other T cell mediators 
(14,15,17).
Several clinical studies investigated the hypoimmunogenic 
and immunosuppressive nature of allogeneic MSCs. Trans-
plantation of allogeneic MSCs showed favorable results in 
patients with osteogenesis imperfecta (18), metachromat-
ic leukodystrophy (19), and severe idiopathic aplastic ane-
mia (20). They were also used for graft vs host disease pre-
vention in the transplantation of hematopoietic stem cells 
(21). Therefore, identification of MSCs’ immunomodulatory 
properties may facilitate their application in hematology 
and organ transplantation protocols.
We demonstrated that tonsil-derived MSCs suppressed 
the growth of T-lymphocytes and secretion of two T-
lymphocyte-specific cytokines. However, MSCs have also 
been shown to impact other T helper subsets involved in 
diseases characterized by immune dysregulation (such as 
IL-17-producing T helper 17 or FoxP3-expressing regula-
tory T cells) (22). Additionally, MSCs suppress DC matura-
tion, and inhibit B cell proliferation, differentiation, and 
chemotaxis. Therefore, additional studies are required to 
completely understand the hierarchy of tonsil-derived 
MSC-associated immunomodulators and determine 
whether tonsil-derived MSCs can trigger the harmful 
T-cell effector behavior (23).
Our study did not include children with histopathological 
diagnosis or microanatomical architecture other than hy-
pertrophic tonsils. While the existing data show only lim-
ited impact of distinct tonsillar histopathology on morpho-
logic changes (hypertrophic changes in palatine tonsil are 
driven only by the germinal center expansion) (24), further 
studies are needed to determine the cell-intrinsic proper-
ties of palatine tonsil-derived MSCs removed for different 
non-malignant reasons.
The limitations of our study include a limited insight into 
T-MSC mechanisms involved in the immune response sup-
pression and selective focus on Th1 and Th2 functions, 
whereas other populations with defined pathogenic role in 
human disease (eg, Th17 and regulatory T cells) remained 
unexplored (22). Recent murine model demonstrated that 
tonsil-derived MSCs expressed both the membrane-bound 
and soluble forms of programmed death-ligand 1 (PD-L1), 
which distinguishes them from MSCs derived from other 
organs. It also found that T-MSC-derived PD-L1 effectively 
suppressed Th17 differentiation in autoimmune diseases 
such as psoriasis (13).
Despite these limitations, our study offers an initial assess-
ment of immunomodulatory properties of tonsil-derived 
MSCs in human samples. Further research is warranted to 
better explain the mechanisms behind the observed im-
munosuppressive effect and to provide a foundation for 
translational consideration.
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